Glasgow, UK, 21 September 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal.
News
York, UK, 21 September 2021: The European Laboratory Research & Innovation Group (ELRIG) UK today announced it will launch its equality, diversity, and inclusion (EDI) guiding principles at Drug Discovery 2021. The principles were developed with the support of Equality, Diversity and Inclusion in Science and Health (EDIS), a coalition of organisations working to improve EDI within the science and health research sectors, and the ELRIG community.
- Blackstone portfolio company BioMed Realty acquires 15-acre Cambridge International Technology Park and 27-acre plot at Granta Park in Cambridge
- Estimated £850 million investment expected to deliver approximately 800,000 square feet of in-demand Grade A purpose-built lab and office space in Cambridge, creating up to 2,700 jobs
- Acquisitions mark vote of confidence from Blackstone in the UK and the growth of the nation’s pioneering life sciences sector, and are supported by BioMed’s 870,000 square feet UK portfolio currently 100% fully leased
We have advised Tyk, a London-based global tech company, on its $35 million growth equity funding round led by new investors Scottish Equity Partners (SEP), alongside existing investors MMC Ventures. Tyk will use the funding to reach new markets and accelerate product development.
Tyk’s innovative API management solution helps to build mission-critical systems in highly regulated industries such as financial services, healthcare, and government. It is used by some of the world’s largest enterprises such as Societe Generale, Starbucks and Domino’s.
We have advised Artificial Intelligence (AI) company Peak on its Series C funding, which raised $75 million.
This is the second round of funding for Peak in 2021, after completing a $21 million round of Series B funding in February, also advised by Taylor Wessing.
In total the company has raised $119 million, with SoftBank Vision Fund 2 leading Series C, supported by existing investors MMC Ventures, Oxx, Praetura Ventures, Arete and Octopus Ventures.
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES
LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021. Dr. Martin Murphy, who previously served as chairman, will continue to serve as a non-executive Board member.
IBX, a global leader in biobanking, bioprocessing and analytics, has acquired UK based biospecimen storage specialists Roylance Pharma
“The team and capabilities within Roylance Pharma perfectly complement those within IBX. Establishing a solid biobanking and bioprocessing hub in the UK servicing Europe, reinforces not only the IBX strategy and mission but also our proposition to clients and commitment to providing world leading biomaterial services,” said Grimwood.
CY Partners are delighted to announce the opening of their new office in London over the summer. It comes on the back of several years’ growth within the southern region for this niche science recruitment firm originating from Newcastle. In the London office currently works the wonderful Neil Walton and Matt Williams with support in payroll, marketing and key account servicing coming from the wider CY Partners team. They are looking to expand imminently so get in touch if you’re interested in joining them!
AMSBIO has launched STEM-CELLBANKER® EX - a next generation cryopreservation product that eliminates the need for the traditional washing steps required in cell therapy product development.